An interventional study of Sildenafil 2% and Minoxidil 5 % in Androgenic Alopecia, sponsored by Mohammed Abd El Mawgoud Amer. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-11.
Sponsored by Mohammed Abd El Mawgoud Amer · Not applicable, Interventional, and Treatment
Androgenetic alopecia (AGA) is hair loss with specific clinical pattern, It Is characterized by follicular miniaturization, which occurs due to systemic androgens and genetic factors. Prevalence differs according to ethnic groups. It is more common and more severe in white men than in Asian and black men. The incidence increases with age. According to Hamilton's study, the prevalence is 30% in men at the age of 30, and 50% in the age of 50. Generally, the age of onset is the 3rd and 4th decade.
Androgenetic alopecia may affect self-esteem and quality of life in several affected individuals. There are two FDA-approved drugs for pattern baldness: topical minoxidil and finasteride, both of which require at least a 4- to 6-month trial before noticing improvement and must be used indefinitely to maintain a response. As such, medication adherence often can be poor. Furthermore, initiation of the drug may cause an initial shedding phase.
Minoxidil was the first and, so far, the only topical product that has been FDA approved for the treatment of AGA. Minoxidil was originally developed as an oral medication for hypertension. Hypertrichosis was found in 24-100 % of patients treated with oral minoxidil, which led to the treatment of AGA with topical minoxidil.
Androgenic Alopecia is caused by the overproduction of 5αdihydrotestosterone (5α-DHT), a potent androgen within the hair follicle, specifically the dermal papilla (DP) cells that are the main regulators of hair growth and are the only site of 5α-DHT action.
Sildenafil is a selective inhibitor of phosphodiesterase 5 and was originally developed as an anti-anginal drug due to its vasodilatory and antiplatelet coagulation properties. Sildenafil enhances the proliferation of human dermal papilla cells and up-regulates the mRNA expression of vascular endothelial growth factor and platelet-derived growth factor (PDGF) which are responsible for hair growth.
Topical sildenafil 1% has been used in the treatment of male androgenic alopecia.
609 studies on the registry are indexed under Alopecia; 131 are open to participants now.
This study's planned enrollment of 50 is above the median of 45 across 513 interventional studies indexed under Alopecia.
Browse Alopecia studies →This is the only study on the registry with Mohammed Abd El Mawgoud Amer as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
will receive topical sildenafil 2% twice daily for 6 months.
Drug: Sildenafil 2%
will receive topical minoxidil 5 % twice daily for 6 months
Drug: Minoxidil 5 %
Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
Also known as: Local Scalp Injection
Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
Also known as: Local Scalp Injection
Improvement changes
improvement will be assessed by comparing the trichoscopic photos before and after treatment as regard hair density
Time frame: 6 months
Patient's satisfaction
by asking the patients and changes in dermatology life Quality Index score as it reflects the quality of life related to skin manifestations
Time frame: 6 months
Complications
infection and bleeding
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.